新股消息 | 博銳生物遞表港交所 擁有八款商業化產品

Company Overview - Zhejiang Borui Biopharmaceutical Co., Ltd. is a leading integrated biopharmaceutical company in China, focusing on providing comprehensive immunotherapy solutions for patients with autoimmune and inflammatory diseases, as well as tumor immunology diseases [3] - The company has been ranked first among Chinese pharmaceutical companies in terms of revenue from biologics for autoimmune diseases for two consecutive years starting in 2023, according to Frost & Sullivan [3] - Borui Biopharmaceutical strategically focuses on immunotherapy, utilizing immune science to regulate immune function to address diseases where immune dysregulation plays a critical role [3] Product Portfolio - The innovative product portfolio includes first-in-class and best-in-class therapies such as IL-17A/F inhibitor Beijiele® (Bicizumab), the first and only innovative CD20 monoclonal antibody Anruisi (Zebetuzumab), and BR2251, a potential first-in-class gout medication with a differentiated mechanism of action [4] - The company has established one of the most competitive and comprehensive immunotherapy product portfolios in the industry, supported by eight commercialized products and a continuously expanding pipeline of innovative therapies [4] Financial Performance - The company reported revenues of approximately RMB 1.257 billion, RMB 1.623 billion, and RMB 1.379 billion for the fiscal years ending in 2023, 2024, and the nine months ending September 30, 2025, respectively [5] - The profit attributable to equity shareholders for the same periods was RMB 19.01 million, RMB 91.30 million, and RMB 121.84 million [6] - The gross profit margins for the fiscal years were recorded at 82.2%, 79.2%, and 74.4% for 2023, 2024, and the nine months ending September 30, 2025, respectively [8] Industry Overview - The autoimmune disease market is one of the fastest-growing sectors in the global pharmaceutical market, with a projected compound annual growth rate (CAGR) of 21.9%, expanding from RMB 174 billion in 2020 to RMB 328 billion by 2024, and expected to reach RMB 2,899 billion by 2035 [10] - The market for biologics in autoimmune diseases is also rapidly expanding, with a CAGR of 42.5%, growing from RMB 42 billion in 2020 to RMB 171 billion by 2024, and projected to reach RMB 2,126 billion by 2035 [10] - The tumor immunology market is expected to grow significantly, with the tumor immunotherapy drugs market in China projected to expand from RMB 148 billion in 2020 to RMB 293 billion by 2024, with a CAGR of 18.5%, and further to RMB 4,954 billion by 2035 [13]